Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
about
Other targeted drugs in melanomaMaximising the potential of AKT inhibitors as anti-cancer treatmentsA Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer.Phase 1 pharmacokinetic study of the oral pan-AKT inhibitor MK-2206 in Japanese patients with advanced solid tumors.Concomitant inhibition of receptor tyrosine kinases and downstream AKT synergistically inhibited growth of KRAS/BRAF mutant colorectal cancer cells.Multicenter phase II study of the AKT inhibitor MK-2206 in recurrent or metastatic nasopharyngeal carcinoma from patients in the mayo phase II consortium and the cancer therapeutics research group (MC1079).Integrated Akt/PKB signaling in immunomodulation and its potential role in cancer immunotherapy.Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein BiomarkersMK-2206 induces apoptosis of AML cells and enhances the cytotoxicity of cytarabine.Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.Akt as a target for cancer therapy: more is not always better (lessons from studies in mice).AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma.Waldenstrom macroglobulinemia cells devoid of BTKC481S or CXCR4WHIM-like mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment.Dynein axonemal heavy chain 8 promotes androgen receptor activity and associates with prostate cancer progression.Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma.A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.Implementing diffusion-weighted MRI for body imaging in prospective multicentre trials: current considerations and future perspectives.Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging.Effect of Akt activation and experimental pharmacological inhibition on responses to neoadjuvant chemoradiotherapy in rectal cancer.Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.Hippo-mediated suppression of IRS2/AKT signaling prevents hepatic steatosis and liver cancer.A phase I, open-label, two-stage study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral AKT inhibitor GSK2141795 in patients with solid tumors.Challenges in combining novel molecularly targeted agents in cancer medicine.
P2860
Q26775594-AC2476AD-5FFC-4AC9-959A-28FB787E3ADFQ28072254-201C3D4E-08F4-4A17-AE3B-5B7E54D29455Q33900807-B38B104D-D7BD-494F-8297-BA40B6619A38Q35889628-4A999A13-5D4D-4BBD-A45B-54A5C129F631Q37706287-91E52E06-B1D5-4871-9721-3947CD177D0EQ38385856-601F7ED1-B103-47BA-9AB3-CB0DAFA7BDF1Q38526844-0B4A9048-6829-4D9C-8FCC-2678109B603FQ38847931-71CB5C5A-2BED-435C-BFBC-E42D0058EF88Q38862452-41D484BD-092D-484A-BAB2-9253A9E5D978Q38912656-A5EAE7D4-34AD-43EA-9DF1-FC5967320FF3Q39338602-56E3855A-D498-4F70-AB6B-220F3966E6AAQ40154948-1278F955-0F6F-4307-8626-98B3CF8F2F94Q40397988-D8398998-3AF8-43AE-9094-2AC62966CDC4Q41070355-74F194E8-5244-4D9B-8F02-7ACA206FA0F4Q41263669-CE154AF8-8D34-4184-AA75-F68A613F6209Q42282892-BCA0F710-59D5-4F30-9AD5-73E1616C5802Q46139159-DBCBFC4D-5B47-4EF8-A484-BD22E390C1E9Q47909847-C16CCF56-0FC4-4A37-A1C8-53CC99EA15C9Q48115847-E1D30370-901F-4B3D-95C4-83072E215210Q48229427-4634E1B4-7C54-4C7D-9C61-C8FD12268CD9Q48241016-9FDFAAE4-04F5-4840-BCBF-8E981A97B128Q49393542-10A417B6-AE56-4033-A654-2E7564121B79Q50199746-8D4F87C7-C783-47CC-A62F-E0C96477C990Q52611153-2970AEF7-7576-4572-B378-758A36EAE4E3Q54314188-47C107E2-971D-4E72-9885-E1385B1E75E3
P2860
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Interrogating two schedules of ...... functional imaging biomarkers.
@ast
Interrogating two schedules of ...... functional imaging biomarkers.
@en
Interrogating two schedules of ...... functional imaging biomarkers.
@nl
type
label
Interrogating two schedules of ...... functional imaging biomarkers.
@ast
Interrogating two schedules of ...... functional imaging biomarkers.
@en
Interrogating two schedules of ...... functional imaging biomarkers.
@nl
prefLabel
Interrogating two schedules of ...... functional imaging biomarkers.
@ast
Interrogating two schedules of ...... functional imaging biomarkers.
@en
Interrogating two schedules of ...... functional imaging biomarkers.
@nl
P2093
P2860
P1476
Interrogating two schedules of ...... functional imaging biomarkers.
@en
P2093
Amita Patnaik
Andrea Biondo
Anthony W Tolcher
Daniel M Sullivan
David Olmos
Ernestina Tetteh
Ivy Fearen
Johann S de Bono
Karen Swales
Kyriakos P Papadopoulos
P2860
P304
P356
10.1158/1078-0432.CCR-14-0868
P407
P577
2014-09-19T00:00:00Z